Apidra 100 [iU]/mL
insulin glulisine · INJECTION, SOLUTION · sanofi-aventis U.S. LLC
No Recall HistoryCurrently in Shortage
Plain English
Apidra is a injection, solution containing insulin glulisine at 100 [iU]/mL, taken intravenous. Manufactured by sanofi-aventis U.S. LLC.
Key Facts
- Brand Name
- Apidra
- Generic Name
- insulin glulisine
- NDC Code (Product)
0088-2500- Manufacturer
- sanofi-aventis U.S. LLC
- Strength
- 100 [iU]/mL
- Dosage Form
- INJECTION, SOLUTION
- Route
- INTRAVENOUS, SUBCUTANEOUS
- Marketing Status
- Application #
- BLA021629
- Drug Class
- Insulin Analog [EPC]
- Marketing Start
- 02/24/2009
Recall History
No Recall HistoryFrequently Asked Questions
What is Apidra used for?
Apidra contains insulin glulisine. It is a injection, solution taken intravenous. Consult your doctor for specific uses.
Is Apidra a controlled substance?
Apidra is not classified as a controlled substance by the DEA.
What is the generic name for Apidra?
The generic name for Apidra is insulin glulisine. There are 1 other brand versions of insulin glulisine.
What is the NDC code for Apidra 100 [iU]/mL?
The NDC (National Drug Code) for Apidra 100 [iU]/mL is 0088-2500, listed by sanofi-aventis U.S. LLC.